Evidence map›Paper›PMID 38927824›Full record

ArticleBioengineering (Basel, Switzerland)2024

A Novel Dehydrated Human Umbilical Cord Particulate Medical Device: Matrix Characterization, Performance, and Biocompatibility for the Management of Acute and Chronic Wounds.

Dominique Croteau, Molly Buckley, Morgan Mantay, Courtney Brannan, Annelise Roy, Barbara Barbaro, Sarah Griffiths

Abstract read
In one paragraph

Article in Bioengineering (Basel, Switzerland), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Dominique CroteauResearch and Development, Stimlabs LLC, 1225 Northmeadow Parkway, Suite 104, Roswell, GA 30076, USA.ORCID 0000-0001-9274-5314
Molly BuckleyResearch and Development, Stimlabs LLC, 1225 Northmeadow Parkway, Suite 104, Roswell, GA 30076, USA.ORCID 0000-0002-2060-0535
Morgan MantayResearch and Development, Stimlabs LLC, 1225 Northmeadow Parkway, Suite 104, Roswell, GA 30076, USA.ORCID 0000-0001-8698-1556
Courtney BrannanResearch and Development, Stimlabs LLC, 1225 Northmeadow Parkway, Suite 104, Roswell, GA 30076, USA.
Annelise RoyResearch and Development, Stimlabs LLC, 1225 Northmeadow Parkway, Suite 104, Roswell, GA 30076, USA.
Barbara BarbaroResearch and Development, Stimlabs LLC, 1225 Northmeadow Parkway, Suite 104, Roswell, GA 30076, USA.
Sarah GriffithsResearch and Development, Stimlabs LLC, 1225 Northmeadow Parkway, Suite 104, Roswell, GA 30076, USA.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Chronic wounds present a significant socioeconomic burden forecasted to increase in prevalence and cost. Minimally manipulated human placental tissues have been increasingly employed and proven to be advantageous in the treatment of chronic wounds, showing improved clinical outcomes and cost-effectiveness. However, technological advances have been constrained by minimal manipulation and homologous use criteria. This study focuses on the characterization of a novel dehydrated human umbilical cord particulate (dHUCP) medical device, which offers a unique allogeneic technological advancement and the first human birth tissue device for wound management. Characterization analyses illustrated a complex extracellular matrix composition conserved in the dHUCP device compared to native umbilical cord, with abundant collagens and glycosaminoglycans imbibing an intricate porous scaffold. Dermal fibroblasts readily attached to the intact scaffold of the dHUCP device. Furthermore, the dHUCP device elicited a significant paracrine proliferative response in dermal fibroblasts, in contrast to fibrillar collagen, a prevalent wound device. Biocompatibility testing in a porcine full-thickness wound model showed resorption of the dHUCP device and normal granulation tissue maturation during healing. The dHUCP device is a promising advancement in wound management biomaterials, offering a unique combination of structural complexity adept for challenging wound topographies and a microenvironment supportive of tissue regeneration.

Indexed as

cell proliferationcellular, acellular, and matrix-like product (CAMP)cellular- and/or tissue-based product (CTP)chronic and acute woundsparticulate wound deviceplacental tissueskin substituteumbilical cordwound animal modelwound healing

Identifiers

PMID38927824
PMCPMC11200885

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.